Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Comment by MrMonkon Jan 12, 2016 2:31pm
171 Views
Post# 24450801

RE:RE:Consolidation

RE:RE:ConsolidationI've said this before - it's fruitless to try to understand why others are selling.  They have their reasons, and those reasons may not be aligned with yours.  Waste of time - you will never know, and it actually doesn't really matter.  

I like the Oban shares for the medium term. NioGold is worth more than $0.50/share, however that would likely have been all they would have gotten from Agnico/Yamana if they made a direct offer instead of Oban. Now, because we will have Oban shares and a larger business, we can negotiate on the property directly instead of selling the whole company.  Better for shareholders in the long run.  I am curious about the cash raise. I think it might be so Osisko can participate and increase their position. I expect it will be placed quickly. This also makes Oban bigger and better able to negotiate with Agnico/Yamana.

- MM
 
<< Previous
Bullboard Posts
Next >>